Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider

Company Performance - Moderna's stock closed at $55.22, reflecting a +0.77% change, outperforming the S&P 500's gain of 0.16% on the same day [1] - Over the past month, Moderna's shares have declined by 18%, which is significantly worse than the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67% [1] Upcoming Earnings - Moderna is set to release its earnings report on November 7, 2024, with projected earnings of -$1.91 per share, indicating a year-over-year decline of 37.41% [2] - The Zacks Consensus Estimate for revenue is $1.25 billion, down 31.71% from the previous year [2] Full-Year Estimates - The full-year Zacks Consensus Estimates for Moderna indicate earnings of -$9.88 per share and revenue of $3.2 billion, representing year-over-year changes of +19.87% for earnings and -53.33% for revenue [3] Analyst Estimates - Recent modifications to analyst estimates for Moderna reflect evolving short-term business trends, with positive revisions seen as a favorable sign for the company's outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Moderna at 3 (Hold) [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Moderna, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]